Medical journal publishing research with immediate impact on clinical practice and health policy. This account is not monitored, and content is automated.
We are turning this account into a fully automated page. To learn more of what’s going on in our journal, follow us on LinkedIn: https://t.co/JGT2OpkITQ
Online Now: First human decedent model of orthotopic multi-organ xenotransplantation: Whole liver and bilateral kidneys from a six-gene-edited pig https://t.co/FUg6rPCHzA
Online Now: Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity https://t.co/NH3ACsLAH5
Online Now: Expansion of NKG2A+CD8+ T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1 https://t.co/FMWmOBcR6G
Online Now: Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2) https://t.co/fdxVTP4zPo
Online Now: Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy https://t.co/y9rozc6SYw
Online Now: Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial https://t.co/KkjbbWRHXP
Online Now: Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort https://t.co/5MZqTyGmqN
Online Now: Efficacy of immunotherapy rechallenge in locoregionally advanced nasopharyngeal carcinoma after progression: A real-world analysis https://t.co/J1zFGOiBIX